PT  - JOURNAL ARTICLE
AU  - EIKI YAMASAKI
AU  - FUKUTARO SHIMAMOTO
AU  - HIROKI NISHIKAWA
AU  - MASAHIRO GOTO
AU  - MITSUHIKO IWAMOTO
AU  - KOSEI KIMURA
AU  - AKIRA UKIMURA
AU  - NAOFUMI OOSAKA
AU  - KOHEI TANIGUCHI
AU  - FUMIHITO ONO
AU  - TETSUJI TERAZAWA
AU  - TOSHIFUMI YAMAGUCHI
AU  - KEN ASAISHI
AU  - TAKAKO IKEGAMI
AU  - KAZUHISA UCHIYAMA
AU  - SHIRO NAKAMURA
AU  - KAZUHIDE HIGUCHI
TI  - A Prospective Study Regarding the Efficacy and Safety of the BNT162b2 Vaccine in Patients With Solid Malignancies Undergoing Systemic Chemotherapy
AID  - 10.21873/invivo.13015
DP  - 2022 Nov 01
TA  - In Vivo
PG  - 2780--2789
VI  - 36
IP  - 6
4099  - http://iv.iiarjournals.org/content/36/6/2780.short
4100  - http://iv.iiarjournals.org/content/36/6/2780.full
SO  - In Vivo2022 Nov 01; 36
AB  - Background/Aim: To prospectively evaluate the efficacy and safety of the BNT162b2 vaccine in solid cancer patients undergoing systemic chemotherapy (n=63). Patients and Methods: COVID-19 anti-spike protein antibody levels were measured before the first BNT162b2 vaccination, just before the second BNT162b2 vaccination, one month after the second BNT162b2 vaccination, and 3 months after the second BNT162b2 vaccination. Anti-spike protein antibody seropositivity was set at ≥0.8 U/ml. Results: Colorectal cancer was the most commonly observed primary disease (36.5%). ECOG-PS 0 was observed in the majority (52.4%) of patients. The overall response rate and the median (range) anti-spike protein antibody levels in the whole cohort at 3 months after the second BNT162b2 vaccination were 98.4% (62/63) and 206 (0.4-3,813) U/ml. None of the patients required postponement or discontinuation of systemic chemotherapy because of an adverse reaction. Conclusion: The BNT162b vaccine in solid cancer patients undergoing systemic chemotherapy is effective and safe.